Microarray compound screening (μARCS) to identify inhibitors of HIV integrase

被引:25
|
作者
David, CA
Middleton, T
Montgomery, D
Ben Lim, H
Kati, W
Molla, A
Xuei, XL
Warrior, U
Kofron, JL
Burns, DJ
机构
[1] Abbott Labs, Dept Adv Technol 4PN, Global Pharmaceut Prod Div, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biol Screening, Global Pharmaceut Prod Div, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Infect Dis Res, Global Pharmaceut Prod Div, Abbott Pk, IL 60064 USA
关键词
D O I
10.1177/108705710200700309
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A novel high-throughput strand transfer assay has been developed, using Microarray Compound Screening (muARCS) technology, to identify inhibitors of human immunodeficiency virus (HIV) integrase. This technology utilizes agarose matrices to introduce a majority of the reagents throughout the assay. Integration of biotinylated donor DNA with fluorescein isothiocyanate (FITC)-labeled target DNA occurs on a SAM membrane in the presence of integrase. An anti-FITC antibody conjugated to alkaline phosphatase (AP) was used to do an enzyme-linked immunosorbent assay with the SAM. An agarose gel containing AttoPhos, a substrate of AP, was used for detection of the integrase reactions on the SAM. For detection, the AttoPhos gel was separated from the SAM after incubation and then the gel was imaged using an Eagle Eye II closed-circuit device camera system. Potential integrase inhibitors appear as dark spots on the gel image. A library of approximately 250,000 compounds was screened using this HIV integrase strand transfer assay in muARCS format. Compounds from different structural classes were identified in this assay as novel integrase inhibitors.
引用
收藏
页码:259 / 266
页数:8
相关论文
共 50 条
  • [21] Integrase inhibitors to treat HIV/AIDS
    Pommier, Y
    Johnson, AA
    Marchand, C
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) : 236 - 248
  • [22] HIV pharmacotherapy: A review of integrase inhibitors
    Wong, Elaine
    Trustman, Nathan
    Yalong, April
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2016, 29 (02): : 36 - 40
  • [23] Integrase inhibitors to treat HIV/Aids
    Yves Pommier
    Allison A. Johnson
    Christophe Marchand
    Nature Reviews Drug Discovery, 2005, 4 : 236 - 248
  • [24] HIV integrase inhibitors: a new era in the treatment of HIV
    Luis Blanco, Jose
    Whitlock, Gary
    Milinkovic, Ana
    Moyle, Graeme
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (09) : 1313 - 1324
  • [25] Design of inhibitors of the HIV-1 integrase core domain using virtual screening
    Regon, Preetom
    Gogoi, Dhrubajyoti
    Rai, Ashok Kumar
    Bordoloi, Manabjyoti
    Bezbaruah, Rajib Lochan
    BIOINFORMATION, 2014, 10 (02) : 76 - 80
  • [26] Development of a receptor model for efficient in silico screening of HIV-1 integrase inhibitors
    Quevedo, Mario A.
    Ribone, Sergio R.
    Brinon, Margarita C.
    Dehaen, Wim
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2014, 52 : 82 - 90
  • [27] HIV integrase inhibitors - Out of the pipeline and into the clinic
    Havlir, Diane V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04): : 416 - 418
  • [28] Update on Adverse Effects of HIV Integrase Inhibitors
    Kolakowska, Agnieszka
    Maresca, Anaenza Freire
    Collins, Intira Jeannie
    Cailhol, Johann
    CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2019, 11 (04) : 372 - 387
  • [29] Probing chelation motifs in HIV integrase inhibitors
    Agrawal, Arpita
    DeSoto, Jamie
    Fullagar, Jessica L.
    Maddali, Kasthuraiah
    Rostami, Shahrzad
    Richman, Douglas D.
    Pommier, Yves
    Cohen, Seth M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (07) : 2251 - 2256
  • [30] HIV Drug Resistance and the Advent of Integrase Inhibitors
    Peter K. Quashie
    Thibault Mesplède
    Mark A. Wainberg
    Current Infectious Disease Reports, 2013, 15 : 85 - 100